Unveiling the Effects of Triptorelin on Endocrine Profiles: Insights From Healthy, Polycystic Ovary Syndrome, and Hypothalamic Amenorrhea Women

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2023 Oct 9

PMID 37809244

Authors

Riya Kumari

Komal N Muneshwar

Aniket G Pathade

Seema Yelne

Affiliations

Soon will be listed here.

Abstract

Triptorelin, a synthetic gonadotropin-releasing hormone (GnRH) agonist, has garnered increasing attention for its profound effects on endocrine profiles across diverse populations. This review article explores triptorelin's impact on women's health by examining its effects on healthy individuals, those with polycystic ovary syndrome (PCOS), and those experiencing hypothalamic amenorrhea (HA). The mechanism of triptorelin involves a transient surge in gonadotropin release, followed by receptor desensitization, leading to downregulation of the hypothalamus-pituitary-gonadal (HPG) axis. In healthy women, triptorelin's controlled modulation of the HPG axis is a foundation for assisted reproduction techniques. In PCOS, it offers promise in restoring ovulatory function and mitigating hyperandrogenism. For HA individuals, triptorelin's potential to restore proper GnRH pulsatility emerges as a therapeutic avenue. This review emphasizes the importance of personalized approaches based on specific health conditions, highlighting triptorelin's versatility and potential applications beyond its current scope. As research progresses, triptorelin's role in endocrine management is poised to reshape women's health by optimizing hormonal equilibrium and overall well-being.

References

De Leo V, Musacchio M, Cappelli V, Massaro M, Morgante G, Petraglia F . Genetic, hormonal and metabolic aspects of PCOS: an update. Reprod Biol Endocrinol. 2016; 14(1):38. PMC: 4947298. DOI: 10.1186/s12958-016-0173-x. View

Tsutsumi R, Webster N . GnRH pulsatility, the pituitary response and reproductive dysfunction. Endocr J. 2009; 56(6):729-37. PMC: 4307809. DOI: 10.1507/endocrj.k09e-185. View

Argente J, Dunkel L, Kaiser U, Latronico A, Lomniczi A, Soriano-Guillen L . Molecular basis of normal and pathological puberty: from basic mechanisms to clinical implications. Lancet Diabetes Endocrinol. 2023; 11(3):203-216. PMC: 10198266. DOI: 10.1016/S2213-8587(22)00339-4. View

Hoogeveen J, van der Veer E . Side effects of pharmacotherapy on bone with long-acting gonadorelin agonist triptorelin for paraphilia. J Sex Med. 2007; 5(3):626-30. DOI: 10.1111/j.1743-6109.2007.00642.x. View

Witchel S, Oberfield S, Pena A . Polycystic Ovary Syndrome: Pathophysiology, Presentation, and Treatment With Emphasis on Adolescent Girls. J Endocr Soc. 2019; 3(8):1545-1573. PMC: 6676075. DOI: 10.1210/js.2019-00078. View

Griesinger G, Schultz L, Bauer T, Broessner A, Frambach T, Kissler S . Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a "freeze-all" strategy: a prospective.... Fertil Steril. 2011; 95(6):2029-33, 2033.e1. DOI: 10.1016/j.fertnstert.2011.01.163. View

Saadia Z . Follicle Stimulating Hormone (LH: FSH) Ratio in Polycystic Ovary Syndrome (PCOS) - Obese vs. Non- Obese Women. Med Arch. 2020; 74(4):289-293. PMC: 7520057. DOI: 10.5455/medarh.2020.74.289-293. View

Vadakkadath Meethal S, Atwood C . The role of hypothalamic-pituitary-gonadal hormones in the normal structure and functioning of the brain. Cell Mol Life Sci. 2005; 62(3):257-70. DOI: 10.1007/s00018-004-4381-3. View

Sakakibara H, Taga M, Ikeda M, Kurogi K, MINAGUCHI H . Continuous stimulation of gonadotropin-releasing hormone (GnRH) receptors by GnRH agonist decreases pituitary GnRH receptor messenger ribonucleic acid concentration in immature female rats. Endocr J. 1996; 43(1):115-8. DOI: 10.1507/endocrj.43.115. View

10.

Rosenfield R, Ehrmann D . The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocr Rev. 2016; 37(5):467-520. PMC: 5045492. DOI: 10.1210/er.2015-1104. View

11.

Rodriguez Paris V, Bertoldo M . The Mechanism of Androgen Actions in PCOS Etiology. Med Sci (Basel). 2019; 7(9). PMC: 6780983. DOI: 10.3390/medsci7090089. View

12.

Plunk E, Richards S . Endocrine-Disrupting Air Pollutants and Their Effects on the Hypothalamus-Pituitary-Gonadal Axis. Int J Mol Sci. 2020; 21(23). PMC: 7731392. DOI: 10.3390/ijms21239191. View

13.

Khosla S, Oursler M, Monroe D . Estrogen and the skeleton. Trends Endocrinol Metab. 2012; 23(11):576-81. PMC: 3424385. DOI: 10.1016/j.tem.2012.03.008. View

14.

Nozaki M . Hypothalamic-pituitary-gonadal endocrine system in the hagfish. Front Endocrinol (Lausanne). 2014; 4:200. PMC: 3874551. DOI: 10.3389/fendo.2013.00200. View

15.

Lerrant Y, Kottler M, Bergametti F, Moumni M, Counis R . Expression of gonadotropin-releasing hormone (GnRH) receptor gene is altered by GnRH agonist desensitization in a manner similar to that of gonadotropin beta-subunit genes in normal and castrated rat pituitary. Endocrinology. 1995; 136(7):2803-8. DOI: 10.1210/endo.136.7.7789305. View

16.

Ravenna L, Salvatori L, Morrone S, Lubrano C, Cardillo M, Sciarra F . Effects of triptorelin, a gonadotropin-releasing hormone agonist, on the human prostatic cell lines PC3 and LNCaP. J Androl. 2000; 21(4):549-57. View

17.

Ndefo U, Eaton A, Green M . Polycystic ovary syndrome: a review of treatment options with a focus on pharmacological approaches. P T. 2013; 38(6):336-55. PMC: 3737989. View

18.

Beitl K, Dewailly D, Seemann R, Hager M, Bunker J, Mayrhofer D . Polycystic Ovary Syndrome Phenotype D Versus Functional Hypothalamic Amenorrhea With Polycystic Ovarian Morphology: A Retrospective Study About a Frequent Differential Diagnosis. Front Endocrinol (Lausanne). 2022; 13:904706. PMC: 9201247. DOI: 10.3389/fendo.2022.904706. View

19.

Maggi R, Cariboni A, Montagnani Marelli M, Moretti R, Andre V, Marzagalli M . GnRH and GnRH receptors in the pathophysiology of the human female reproductive system. Hum Reprod Update. 2015; 22(3):358-81. DOI: 10.1093/humupd/dmv059. View

20.

Dennett C, Simon J . The role of polycystic ovary syndrome in reproductive and metabolic health: overview and approaches for treatment. Diabetes Spectr. 2015; 28(2):116-20. PMC: 4433074. DOI: 10.2337/diaspect.28.2.116. View